{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-132559","form_type":"8-K","ticker":"MDGL","cik":"0001157601","company_name":"MADRIGAL PHARMACEUTICALS, INC.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.474860+00:00","generated_at":"2026-06-02T16:09:54.641322+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Madrigal posts Q1 net loss of ~$147.5M as Rezdiffra launch ramps up","bullets":["Rezdiffra received FDA accelerated approval on March 14, 2024; first shipments to patients began in April.","No Q1 revenue; operating expenses of $152.0M (up 94% YoY) due to commercial preparation and headcount.","Cash, cash equivalents and marketable securities of $1.1B after $690M gross proceeds from public offering.","Appointed Mardi C. Dier as CFO on February 28, 2024.","European MAA for resmetirom validated and under EMA review."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-132559","json":"https://secwatch.observer/filing/0001193125-24-132559.json","markdown":"https://secwatch.observer/filing/0001193125-24-132559.md","text":"https://secwatch.observer/filing/0001193125-24-132559.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157601/000119312524132559/0001193125-24-132559-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157601/000119312524132559/d828444d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T16:09:54.641322+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"173e38a1c4caec5b650f56f8d3161453ef6d630b","claim":"MADRIGAL PHARMACEUTICALS, INC. reported financial results for first-quarter 2024.","evidence_excerpt":"On May 7, 2024, Madrigal Pharmaceuticals, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fiscal quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1157601/000119312524132559/0001193125-24-132559-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first-quarter 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}